Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015

Meulen, Matthijs van der; Dinmohamed, Avinash G.; Visser, Otto; Doorduijn, Jeanette K.; Bromberg, Jacoline E C

doi:10.1038/leu.2017.128

Cited by 56 publications

(60 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data are supportive of a recent smaller population-based Dutch study showing no improvement in survival in elderly PCNSL patients. 23 Another factor may be the lack of prospectively collected data to guide treatment…”

Section: Discussionmentioning

confidence: 99%

The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades

et al. 2017

View full text Add to dashboard Cite

show abstract

“…PCNSL has traditionally carried a sinister prognosis, and 5-years survival is only 15-30% for these patients (2,5). Despite that improved long-term survival has been reported for this tumor due to the substantial prognosis in therapeutic strategy (6)(7)(8), the overall prognosis remains frustrating, suggesting that intensive study of PCNSL is needed.…”

Section: Introductionmentioning

confidence: 99%

Real-World Impact of Surgical Excision on Overall Survival in Primary Central Nervous System Lymphoma

Deng

Lin

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Substantial controversy still exists regarding the use of surgical excision in the treatment of primary central nervous system lymphoma (PCNSL). This study was aimed to evaluate the survival benefit of surgical excision in PCNSL patients based on a US population. Using the Surveillance, Epidemiology, and End Results (SEER) Program database, a total of 3,543 PCNSL patients were identified from 2000 to 2014 for analysis. Surgical excision was accessed via Kaplan-Meier and multivariate Cox regression survival analyses. Coarsened exact matching (CEM) analysis was additionally employed to intensify our findings. Finally, we found that surgical excision was significantly associated with increased survival over no surgery/biopsy (P < 0.001), and its survival benefit was also independent of baseline prognostic factors. The survival benefit of surgery was also validated in clinically important subsets. CEM analysis further validated the survival advantage of surgery (P < 0.001). Moreover, a novel prediction model with excellent performance was established to estimate the potential benefit from surgical excision of the lesion with respect to the end point of overall survival. The current study supports the favorable impact of surgical excision on clinical outcome in patients with PCNSL. Although further randomized controlled trials are warranted, currently available evidence should be considered in the clinical management of this disease.

show abstract

“…Over the last three decades, the incidence rate has increased, mainly amongst patients >60 years old, and prognosis has improved significantly. 1,2 This prolonged survival has largely been determined by improvements in treatment. 1,3 In systemic diffuse large B-cell lymphoma patients, the addition of rituximab, a chimeric monoclonal antibody targeting the CD20 cell surface protein, to standard treatment has been shown to improve progression-free survival and overall survival.…”

Section: Introductionmentioning

confidence: 99%

“…1,2 This prolonged survival has largely been determined by improvements in treatment. 1,3 In systemic diffuse large B-cell lymphoma patients, the addition of rituximab, a chimeric monoclonal antibody targeting the CD20 cell surface protein, to standard treatment has been shown to improve progression-free survival and overall survival. 4,5 Since most PCNSL are diffuse large B-cell lymphoma (DLBCL), it has been Arm R-MBVP n = 100 Arm: MBVP n = 100…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study

et al. 2020

View full text Add to dashboard Cite

Background: The impact of rituximab on health-related quality of life (HRQoL) in primary central nervous system lymphoma patients is not well known. We determined the impact of rituximab added to standard high-dose methotrexate-based treatment on HRQoL in patients in a large randomised trial. Patients and methods: Patients from a large phase III trial (HOVON 105/ALLG NHL 24), randomly assigned to receive standard chemotherapy with or without rituximab and followed by 30 Gy whole brain radiotherapy (WBRT) in patients 60 years, completed the EORTC QLQ-C30 and QLQ-BN20 questionnaires before and during treatment, and up to 24 months of follow-up or progression. Differences between treatment arms over time in global health status, role functioning, social functioning, fatigue, and motor dysfunction were assessed. Differences !10 points were deemed clinically relevant. The effect of WBRT on HRQoL was analysed in irradiated patients. Results: A total of 160/175 patients eligible for the HRQoL study completed at least one questionnaire and were included. Over time, scores improved statistically significantly and were clinically relevant in both arms. Between arms, there were no differences on any scale (range: À3.8 to þ4.0). Scores on all scales were improved to a clinically relevant extent at 12 and 24 months compared with baseline in both arms, except for fatigue and motor dysfunction at 12 months (À7.4 and À8.8, respectively). In irradiated patients (n ¼ 59), scores in all preselected scales, except motor dysfunction, remained stable up to 24 months compared with shortly after WBRT, overall mean difference ranging between 0.02 and 4.570. Conclusion: Compared with baseline, treatment resulted in improved HRQoL scores. The addition of rituximab to standard chemotherapy did not impact HRQoL over time. WBRT did not result in deterioration of HRQoL in the first 2 years.

show abstract

Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015

Cited by 56 publications

References 15 publications

The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades

The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades

Real-World Impact of Surgical Excision on Overall Survival in Primary Central Nervous System Lymphoma

Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study

Contact Info

Product

Resources

About